Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Kissei Pharmaceutical Co ( (JP:4547) ) just unveiled an update.
Kissei Pharmaceutical Co reported a significant financial performance for Fiscal 2024, with net sales reaching ¥88,330 million, marking a 16.9% increase year-over-year, and an operating profit of ¥5,773 million, a 43.7% rise. The growth was driven by increased sales in both domestic and international markets, particularly through the expansion of products like Linzagolix and Fostamatinib. The company also saw a rise in R&D expenses due to new product developments and licensing agreements, indicating a strategic focus on innovation and market expansion.
More about Kissei Pharmaceutical Co
Kissei Pharmaceutical Co is a company operating in the pharmaceutical industry, focusing on developing and marketing pharmaceuticals. The company is involved in both domestic and international markets, with a particular emphasis on expanding its presence through licensing agreements and marketing authorizations.
Average Trading Volume: 72,814
Technical Sentiment Signal: Strong Buy
Current Market Cap: Yen160.2B
For detailed information about 4547 stock, go to TipRanks’ Stock Analysis page.